News

ACRV
Acrivon Therapeutics, Inc. News

This news view pulls recent coverage and headlines tied to ACRV.

Latest Close

$1.15

1y Change

-$1.15 (-50.00%)

Market Cap

$49,348,432.00

Sector

Healthcare

Industry

Biotechnology

Recommendation

strong_buy

Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights

GlobeNewswire • Nov 16, 2026

Read article

Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB

GlobeNewswire • Nov 6, 2026

Read article

Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

GlobeNewswire • Nov 4, 2026

Read article

Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium

GlobeNewswire • Oct 29, 2026

Read article

Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027

GlobeNewswire • Oct 20, 2026

Read article

What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock

Zacks • Sep 15, 2026

Read article